Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Researchers create radioactive nanoparticles that target lymphoma tumor cells

Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.

22 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Imaging scans do little help to detect relapse of diffuse large B-cell lymphoma

Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found.

17 May 2013

People diagnosed with cancer are more likely to declare bankruptcy

People diagnosed with cancer are more than two-and-a-half times more likely to declare bankruptcy than those without cancer, according to a new study from Fred Hutchinson Cancer Research Center. Researchers also found that younger cancer patients had two- to five-fold higher bankruptcy rates compared to older patients, and that overall bankruptcy filings increased as time passed following diagnosis.

17 May 2013

Depressive symptoms linked to early death in cancer survivors

Depressed cancer survivors are twice as likely to die prematurely than those who do not suffer from depression, irrespective of the cancer site. That's according to a new study, by Floortje Mols and colleagues, from Tilburg University in The Netherlands.

17 May 2013

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.

16 May 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.

14 May 2013

Annual Century for the Cure bike ride supports research on hematologic malignancies

The annual Century for the Cure bike ride that has raised more than $1 million since 2005 for research at The Cancer Institute of New Jersey is now making it possible for new scientific exploration in the area of hematologic malignancies.

14 May 2013

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center have found a combination of drugs to potentially treat chronic lymphocytic leukemia more effectively.

14 May 2013

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).

14 May 2013

Study results suggest that CNL and aCML patients could be treated with FDA-approved drugs

Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers at the Knight Cancer Institute at Oregon Health & Science University.

13 May 2013

John Theurer to host 9th annual neuro-oncology symposium on May 17

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

10 May 2013

Inherited mutations in p53 gene put people at high risk of developing cancers

The understanding of how a powerful protein called p53 protects against cancer development has been upended by a discovery by Walter and Eliza Hall Institute researchers. More than half of human cancers carry defects in the gene for p53, and almost all other cancers, with a normal p53 gene, carry other defects that somehow impair the function of the p53 protein. Inherited mutations in the p53 gene put people at a very high risk of developing a range of cancers.

10 May 2013

Researchers find a way the body can remove injured axons

Many medical issues affect nerves, from injuries in car accidents and side effects of chemotherapy to glaucoma and multiple sclerosis. The common theme in these scenarios is destruction of nerve axons, the long wires that transmit signals to other parts of the body, allowing movement, sight and sense of touch, among other vital functions.

10 May 2013

Lymphoma News and Research

Further Reading

Researchers create radioactive nanoparticles that target lymphoma tumor cells

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Imaging scans do little help to detect relapse of diffuse large B-cell lymphoma

People diagnosed with cancer are more likely to declare bankruptcy

Depressive symptoms linked to early death in cancer survivors

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Annual Century for the Cure bike ride supports research on hematologic malignancies

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

Study results suggest that CNL and aCML patients could be treated with FDA-approved drugs

John Theurer to host 9th annual neuro-oncology symposium on May 17

Inherited mutations in p53 gene put people at high risk of developing cancers

Researchers find a way the body can remove injured axons

New data help explain hospital pricing, but experts caution that Medicare and insurers get much lower rates

First Edition: May 9, 2013

Loyola opens 20-bed unit for patients undergoing stem cell transplants for cancers

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News